Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 6, 2016, Pages 1643-1650

  Roger, Claire ^a,b,c   Wallis, Steven C ^b   Louart, Benjamin ^a,b   Lefrant, Jean Yves ^a,b   Lipman, Jeffrey ^c,d   Muller, Laurent ^a,b   Roberts, Jason A ^c,d  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; BLOOD FLOW VELOCITY; BODY WEIGHT; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOLUME OF DISTRIBUTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BLOOD; COMPARATIVE STUDY; CRITICAL ILLNESS; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEMODIAFILTRATION; HEMOFILTRATION; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PATHOGENICITY; PROCEDURES; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RENAL REPLACEMENT THERAPY; SEPSIS; STATISTICS AND NUMERICAL DATA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CRITICAL ILLNESS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MONTE CARLO METHOD; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84973387034     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw043     Document Type: Article

References (28)

1. Uchino S, Bellomo R, Morimatsu H et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007; 33: 1563-70.
2. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock:2012. Crit Care Med 2013; 41: 580-637.
3. Matzke GR, Aronoff GR, Atkinson AJ Jr et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122-37.
4. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51; quiz 59.
5. Roberts DM, Roberts JA, Roberts MS et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40:1523-8.
6. Pea F, Viale P, Pavan F et al. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007; 46: 997-1038.
7. Wong G, Brinkman A, Benefield RJ et al. An international, multicentre survey of b-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014; 69: 1416-23.
8. Tabah A, DeWaele J, Lipman J et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 2015; 70: 2671-7.
9. Lipman J, Scribante J, Gous AG et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998; 42: 2235-9.
10. Conil JM, Georges B, de Lussy A et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents 2008; 32: 505-10.
11. Pea F, Poz D, Viale P et al. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 2006; 58: 380-6.
12. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
13. Malone RS, Fish DN, Abraham E et al. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45: 2949-54.
14. Wallis SC, Mullany DV, Lipman J et al. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001; 27: 665-72.
15. Spooner AM, Deegan C, D'Arcy DM et al. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous venovenous haemodiafiltration. BMC Clin Pharmacol 2011; 11: 11.
16. Roger C, Muller L, Wallis SC et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother 2016; 71:464-70.
17. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.
18. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-63.
19. Vincent JL, de Mendonca A, Cantraine F et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units:results of a multicenter, prospective study. Working group on 'sepsisrelated problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-800.
20. Tatarinova T, Neely M, Bartroff J et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn 2013; 40:189-99.
21. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monitor 2012; 34: 467-76.
22. Nseir S, Di Pompeo C, Soubrier S et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005; 33: 283-9.
23. Kontou P, Chatzika K, Pitsiou G et al. Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother 2011; 55: 4149-53.
24. Zelenitsky S, Ariano R, Harding G et al. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother 2005; 49:4009-14.
25. Roberts DM, Liu X, Roberts JA et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care 2015; 19: 84.
26. Jamal JA, Udy AA, Lipman J et al. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med 2014; 42: 1640-50.
27. Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11: 218.
28. Vance-Bryan K, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434-61.